Month: September 2024

“Multiple Sclerosis Market”

DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Multiple Sclerosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Multiple Sclerosis market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Key highlights from the Multiple Sclerosis Market Report:

• In 2023, there were approximately 1.2 million prevalent cases of multiple sclerosis (MS) across the 7MM (United States, EU4, UK, and Japan). The increase in MS cases is attributed to enhanced diagnostic capabilities and screening, limited access to genetic counseling and family planning, and low public awareness.

• Among current treatments for MS, Ocrevus is anticipated to achieve the largest market share in the US by 2034. The overall MS therapeutic market is expected to experience significant growth at a robust compound annual growth rate (CAGR) due to the anticipated approval of new therapies, improved diagnostic methods, and increased research and development in pharmaceutical treatments.

• In August 2024, ImmPACT Bio received FDA clearance to start clinical trials for its CD19/CD20 bispecific CAR-T cell therapy in multiple sclerosis (MS) patients.

• In Jan 2024, Kyverna’s KYV-101 Receives U.S. FDA Clearance for Treatment of Patients With Refractory, Progressive Multiple Sclerosis in the KYSA-7 Phase 2 Trial

• In March 2022,  Pipeline Therapeutics announced that it is all set to commence the Phase Ib/IIa clinical trial of its lead program, PIPE-307, to treat relapsing-remitting multiple sclerosis (RRMS) patients. The move comes after the company obtained clearance for its investigational new drug application from the US Food and Drug Administration (FDA) to launch the trial.

• In June 2022 the Food and Drug Administration (FDA) extended the review period for the Biologics License Application (BLA) for ublituximab for the treatment of patients with relapsing forms of multiple sclerosis (RMS).The new Prescription Drug User Fee Act (PDUFA) target date is December 28, 2022. The FDA extended the goal date to allow time to review additional clinical information that was deemed to be a major amendment to the application.

• In June 2022, Tiziana Life Sciences reported positive clinical results from the second patient with Secondary Progressive Multiple Sclerosis (SPMS) in the ongoing study as part of an expanded access program at the Brigham and Women’s Hospital (BWH), Boston, MA. These results confirmed the previously reported data, from the first SPMS patient after three months of treatment of the first SPMS patient. The treatment with foralumab, a fully human anti-CD3 monoclonal antibody, was well-tolerated and improved clinical and PET imaging analyses.

• In June 2022, Pasithea Therapeutics Corp. announced its acquisition of Alpha-5 integrin, LLC (“Alpha-5”), a privately-held preclinical-stage company developing a monoclonal antibody (mAbs) for the treatment of amyotrophic lateral sclerosis (“ALS”) and other neuroinflammatory disorders, such as Multiple Sclerosis (“MS”).

• In April 2021, Samsung Biologics and TG announced an expansion of a large-scale contract manufacturing deal for the supply of TG Therapeutics’ ublituximab, an investigational anti-CD20 monoclonal antibody.

• On March 28, 2019, the US FDA approved OCREVUS (ocrelizumab) to treat adult patients with relapsing forms of MS and PPMS. This is the first drug approved by the FDA for PPMS.

• On October 30, 2019, Biogen Inc. and Alkermes announced the US FDA approval of VUMERITY (diroximel fumarate) to treat MS. The approval was based on a New Drug Application (NDA) submitted under the 505(b) (2) filing pathway. It included data from pharmacokinetic bridging studies comparing Vumerity and Tecfidera to establish bioequivalence and relied, in part, on the FDA’s findings of safety and efficacy for Tecfidera.

Read detailed insights on Multiple Sclerosis market outlook 2034 @ https://www.delveinsight.com/sample-request/multiple-sclerosis-market

Multiple Sclerosis Overview

Multiple Sclerosis (MS) is an autoimmune disease that affects the central nervous system, where the immune system mistakenly attacks myelin, the protective coating of nerve fibers. This results in neurological impairment during episodes that can be followed by periods of remission. Damage to myelin causes scar tissue (sclerosis), which disrupts nerve impulses between the brain and spinal cord.

MS typically begins in a person’s late 20s, with symptoms including visual and sensory disturbances, limb weakness, gait issues, and bladder and bowel dysfunction. Initial symptoms may partially improve, but the disease can lead to progressive disability over time. MS can manifest in various physical, emotional, and psychological symptoms, differing in severity among individuals.

The four main types of MS are:

1. Relapsing-Remitting MS (RRMS)

2. Secondary-Progressive MS (SPMS)

3. Primary-Progressive MS (PPMS)

4. Progressive-Relapsing MS (PRMS)

Diagnosing MS is complex and involves ruling out other conditions. It typically includes a thorough medical history, physical examination, and neurological assessment. Diagnostic tests may include:

– MRI scans of the brain and spinal cord to identify MS lesions, sometimes using contrast dye.

– Lumbar puncture (spinal tap) to examine cerebrospinal fluid for markers of MS and rule out other conditions.

While there is no cure for MS, various treatments can improve long-term outcomes. Treatment goals focus on reducing relapses, slowing disease progression, and maintaining functionality. Disease-modifying therapies (DMTs) are used to manage the underlying immune disorder and are primarily approved for relapsing forms of MS. Adherence to DMTs can be challenging, highlighting the need for better persistence with treatment strategies.

Overall, managing MS involves comprehensive care to improve quality of life and mitigate disease progression.

Multiple Sclerosis Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

Multiple Sclerosis Epidemiology Insights:

• In 2023, there were approximately 728,000 prevalent cases of multiple sclerosis (MS) in the United States, with significant changes expected by 2034.

• In Germany, the prevalence of MS was about 61,000 cases in males and 150,000 cases in females in 2023. 

• In the UK, there was a notable disparity in MS cases based on phenotype. Relapsing-Remitting MS (RRMS) was significantly more common than Clinically Isolated Syndrome (CIS), Secondary Progressive MS (SPMS), and Primary Progressive MS (PPMS). In 2023, there were around 80,000 cases of RRMS, with these numbers anticipated to fluctuate throughout the study period from 2020 to 2034.

• France reported approximately 79,000 prevalent cases of MS in 2023, with further changes expected by 2034.

• Japan had about 5,000 prevalent cases of MS in 2023, and these numbers are also anticipated to fluctuate by 2034.

• According to DelveInsight’s analysts, in the US, there were 37 cases of MS among individuals aged 0-18 and approximately 728,000 cases in those aged 19 and older in 2023. These numbers are projected to evolve over the study period from 2020 to 2034.

• In the EU4 and the UK, Germany reported the highest number of MS cases, with around 210,000 prevalent cases in 2023. This figure is also expected to change during the study period from 2020 to 2034.

• In Spain, the prevalence of MS subtypes in 2023 included 826 cases of Clinically Isolated Syndrome, 34,786 cases of Relapsing-Remitting MS (RRMS), 7,205 cases of Secondary Progressive MS (SPMS), and 3,075 cases of Primary Progressive MS (PPMS). DelveInsight’s projections indicate that these numbers will increase during the forecast period from 2024 to 2034.

Multiple Sclerosis Therapies

• Immune Response BioPharma, Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, Bayer HealthCare Pharmaceuticals, Novartis, Biogen, Genentech

Multiple Sclerosis Therapies

• GILENYA (Fingolimod), Vumerity (Diroximel fumarate), OCREVUS (Ocrelizumab)

Learn How the Multiple Sclerosis Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/report-store/multiple-sclerosis-market

Multiple Sclerosis Treatment Market

The current treatment approach for multiple sclerosis (MS) primarily aims to slow disease progression and manage symptoms during MS attacks. Treatment decisions are typically based on the specific MS phenotype and the level of disability, as measured by the Expanded Disability Status Scale (EDSS). For patients with mild symptoms, treatment may not be necessary.

Although there is no cure for Multiple Sclerosis, recent trends have shown a significant increase in the use of Disease Modifying Therapies (DMTs). These therapies are designed to slow disease progression and improve the quality-adjusted life years for patients.

To manage acute MS attacks, symptomatic treatments include:

– Corticosteroids: Oral prednisone and intravenous methylprednisolone are used to reduce nerve inflammation. Common side effects include insomnia, elevated blood pressure and blood glucose levels, mood swings, and fluid retention.

– Plasma Exchange (Plasmapheresis): This procedure involves removing the liquid part of the blood (plasma), mixing the blood cells with a protein solution (albumin), and returning it to the body. It is used for patients who do not respond to steroids.

The major focus in the Multiple Sclerosis market is on treatments that modify disease progression, aiming to extend progression-free survival and improve quality-adjusted life years. Disease Modifying Treatments (DMTs) are tailored to the four clinical phenotypes of MS.

Selecting the appropriate DMT involves careful evaluation of factors such as disease duration and severity, the effectiveness of previous treatments, other health conditions, cost, and considerations related to pregnancy. The MS treatment landscape includes a robust pipeline of potential new therapies from leading pharmaceutical companies, addressing the ongoing unmet needs in the market.

Leading Players in the Multiple Sclerosis Therapeutics Market Include:

Multiple Sclerosis Companies working in the market are Immune Response BioPharma, Inc., Clene Nanomedicine, Sanofi, Merck Healthcare KGaA, Bayer HealthCare Pharmaceuticals, Novartis, Biogen, Genentech, and others.

Multiple Sclerosis Report Covers the In-depth Assessment of the Emerging Multiple Sclerosis Drugs & Key Companies. Download the Multiple Sclerosis Market Sample Report to Learn More @ https://www.delveinsight.com/sample-request/multiple-sclerosis-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. Multiple Sclerosis Competitive Intelligence Analysis

4. Multiple Sclerosis Market Overview at a Glance

5. Multiple Sclerosis Disease Background and Overview

6. Multiple Sclerosis Patient Journey

7. Multiple Sclerosis Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Multiple Sclerosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Multiple Sclerosis Unmet Needs

10. Key Endpoints of Multiple Sclerosis Treatment

11. Multiple Sclerosis Marketed Products

12. Multiple Sclerosis Emerging Drugs and Latest Therapeutic Advances

13. Multiple Sclerosis Seven Major Market Analysis

14. Attribute Analysis

15. Multiple Sclerosis Market Outlook (In US, EU5, and Japan)

16. Multiple Sclerosis Access and Reimbursement Overview

17. KOL Views on the Multiple Sclerosis Market

18. Multiple Sclerosis Market Drivers

19. Multiple Sclerosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Adalimumab Biosimilar Market  | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Market Assessment 2034 | Multiple Sclerosis Therapies, FDA Approval, Clinical trials, Prevalence, Treatment Algorithms and Companies by DelveInsight | Immune Response BioPharma

“Iron Deficiency Anemia Market”

DelveInsight’s “Iron Deficiency Anemia Market Insights, Epidemiology, and Market Forecast 2034” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Iron Deficiency Anemia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The Iron Deficiency Anemia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2020 to 2034. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Key highlights from the Iron Deficiency Anemia Market Report:

• In 2023, the Iron Deficiency Anemia market size across the 7MM (United States, EU4, UK, and Japan) was approximately USD 1,400 million. The market is expected to see significant growth due to increased adoption of existing treatments, the anticipated launch of one-time gene therapies, and greater awareness of the condition.

• The United States holds the largest share of the Iron Deficiency Anemia market, accounting for about 78%, compared to the EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

• Oral Ferrous Products (OFPs), including ferrous sulfate, ferrous fumarate, and ferrous gluconate, are the most common treatments for IDA due to their cost-effectiveness. However, OFPs currently represent only 10-15% of the total IDA market. This is largely due to the prevalence of generic versions and issues with patient adherence, primarily due to gastrointestinal side effects.

• In the early stages of IDA, particularly mild to moderate cases, oral iron supplements are often prescribed. These supplements come in various forms, including tablets, pills, and syrups. In 2019, the FDA approved ACCRUFER for adults who had previously discontinued oral ferrous products due to ineffectiveness or intolerance. Similarly, in 2017, the FDA approved AURYXIA for treating IDA in adults with chronic kidney disease (CKD) who were intolerant of or had an inadequate response to oral iron supplements.

• Due to low adherence rates to oral iron supplements, intravenous iron options are considered more effective. Options include INJECTAFER, VENOFER, and FERAHEME. However, these treatments often require clinic visits for administration and can impact patients’ quality of life.

• Rockwell Medical introduced TRIFERIC (dialysate) and TRIFERIC AVNU (intravenous) in the U.S. in late 2019 and early 2021, respectively. Despite these launches, limited market adoption, unfavorable reimbursement, and a lack of interest from other companies led Rockwell Medical to discontinue the NDA for TRIFERIC and TRIFERIC AVNU in the fourth quarter of 2022.

• The IDA market is expected to grow due to the introduction of new oral iron supplements with fewer side effects, an increase in IDA cases driven by lifestyle changes and risk factors like malaria, and other factors. However, widespread use of OTC medications, the availability of generics, the economic burden on patients, and a lack of a robust pipeline could hinder market growth.

Read detailed insights on Iron Deficiency Anemia market outlook 2034 @ https://www.delveinsight.com/sample-request/iron-deficiency-anemia-market

Iron Deficiency Anemia Overview

Iron deficiency anemia (IDA) is the most common type of anemia, occurring when the body does not have enough iron to produce sufficient hemoglobin. Hemoglobin is essential for transporting oxygen throughout the body, so low iron levels can impair oxygen delivery. The severity of IDA can range from mild to severe, depending on the degree of iron deficiency.

Diagnosing IDA generally starts with a complete blood count (CBC) test, followed by additional blood tests to evaluate the extent of the deficiency and identify potential causes. These further tests often include measuring iron levels, ferritin, and total iron-binding capacity, as well as assessing reticulocyte counts and examining peripheral blood smears. If gastrointestinal bleeding is suspected, diagnostic procedures such as fecal occult blood tests, upper endoscopy, and colonoscopy may be performed. Additional tests might be conducted to assess inflammation markers, nutrient levels, and bone marrow health to pinpoint the underlying cause of the anemia.

The Iron Deficiency Anemia report offers a thorough overview of its pathophysiology, diagnostic approaches, and treatment strategies, including real-world examples of patient experiences from symptom onset through diagnosis and management.

Treatment for Iron Deficiency Anemia

The treatment for IDA varies based on its cause and severity and may involve iron supplements, medical procedures, surgery, and dietary adjustments. For severe cases, intravenous (IV) iron therapy or a blood transfusion may be necessary. The primary goals of treatment are to address the underlying cause of IDA and to restore normal levels of red blood cells, hemoglobin, and iron.

If gastrointestinal bleeding is the cause, procedures such as upper endoscopy or colonoscopy may be performed to stop the bleeding. For patients with chronic kidney disease and IDA, erythropoiesis-stimulating agents (ESAs) may be prescribed. These medications stimulate the bone marrow to produce more red blood cells and are typically used in conjunction with iron therapy or IV iron, particularly if iron therapy alone is insufficient.

For patients who cannot tolerate or absorb oral iron supplements—such as those who have had gastrectomy, gastrojejunostomy, bariatric surgery, or other small bowel surgeries—parenteral (injectable) iron therapies may be used. Common parenteral iron options include VENOFER, FERINJECT, FERAHEME, and MONOFER.

Iron Deficiency Anemia Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders. 

Iron Deficiency Anemia Epidemiology Insights:

• In 2023, the total number of prevalent cases of Iron Deficiency Anemia (IDA) in the United States was approximately 9,510,600. Among the EU4 countries (Germany, Spain, Italy, France) and the UK, the UK had the highest number of diagnosed prevalent cases, while France reported the fewest.

• According to estimates from DelveInsight’s consultants, about two-thirds of the diagnosed cases of IDA were classified as mild. The condition was notably more common in women than in men, with women accounting for approximately 65% of cases in 2023.

• In the United States, IDA associated with chronic kidney disease represented around 30% of all IDA cases by pathology in 2023.

Key Iron Deficiency Anemia Companies

• Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysis

Iron Deficiency Anemia Therapies

• MPB-1514 (IOP Injection), IDAX (IHAT-02), FERACCRU/ACCRUFeR (Ferric Maltol/ ST10), MONOFER (Iron Isomaltoside 1000/ Monoferric/ ferricderisomaltose/ NS-32)

Learn How the Iron Deficiency Anemia Market Will Evolve and Grow by 2034 @ https://www.delveinsight.com/sample-request/iron-deficiency-anemia-market

Iron Deficiency Anemia Market Outlook

Effectively managing Iron Deficiency Anemia (IDA) involves diagnosing the underlying cause of the iron deficiency and implementing appropriate treatments, including dietary changes and iron supplementation. Oral iron therapy is the primary treatment for patients who do not have contraindications. Currently, IDA treatment options include oral iron supplements (both over-the-counter and prescription), parenteral iron therapies (such as intravenous treatments), blood transfusions, surgical interventions, and other modalities. For patients with chronic kidney disease (CKD) and IDA, erythropoiesis-stimulating agents (ESAs) may be recommended.

VENOFER (Ferric Oxyhydroxide), approved by the FDA in November 2000, is used to treat IDA in chronic hemodialysis patients receiving erythropoietin therapy. It received additional FDA approval in June 2005 for managing IDA in CKD patients not on dialysis. INJECTAFER was approved in Europe in June 2007 and in May 2021, the FDA approved a single 1000 mg dose of Injectafer for adult IDA patients who are intolerant to oral iron, have an unsatisfactory response to oral iron, or have non-dialysis dependent CKD. Other FDA-approved therapies include AURYXIA, FERACCRU/ACCRUFeR, and MONOFER. Numerous over-the-counter iron supplements and salts, available at affordable prices, are widely used by patients. These supplements are available in both ferrous and ferric salt forms, and several consumer health companies are also developing non-drug supplements to combat iron deficiency.

Despite the range of approved treatments, there are still unmet needs in the management of IDA. Companies like MegaPro Biomedical (developing MPB-1514 (IOP Injection)) and Nemysis (developing IDAX (IHAT-02)) are working on novel therapies to address these gaps and improve treatment options for IDA.

Leading Players in the Iron Deficiency Anemia Therapeutics Market Include:

Iron Deficiency Anemia Companies working in the market are Akebia Therapeutics, Shield Therapeutics, AMAG Pharmaceuticals, Pharmacosmos Therapeutics, Vifor Pharma, Vifor Pharma, American Regent, MegaPro Biomedical, Nemysis, and others.

Iron Deficiency Anemia Report Covers the In-depth Assessment of the Emerging Iron Deficiency Anemia Drugs & Key Companies. Download the Iron Deficiency Anemia Market Sample Report to Learn More @ https://www.delveinsight.com/report-store/iron-deficiency-anemia-market

Table of Contents

1. Key Insights

2. Executive Summary 

3. Iron Deficiency Anemia Competitive Intelligence Analysis

4. Iron Deficiency Anemia Market Overview at a Glance

5. Iron Deficiency Anemia Disease Background and Overview

6. Iron Deficiency Anemia Patient Journey

7. Iron Deficiency Anemia Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Iron Deficiency Anemia Treatment Algorithm, Current Treatment, and Medical Practices

9. Iron Deficiency Anemia Unmet Needs

10. Key Endpoints of Iron Deficiency Anemia Treatment

11. Iron Deficiency Anemia Marketed Products

12. Iron Deficiency Anemia Emerging Drugs and Latest Therapeutic Advances

13. Iron Deficiency Anemia Seven Major Market Analysis

14. Attribute Analysis

15. Iron Deficiency Anemia Market Outlook (In US, EU5, and Japan)

16. Iron Deficiency Anemia Access and Reimbursement Overview

17. KOL Views on the Iron Deficiency Anemia Market

18. Iron Deficiency Anemia Market Drivers

19. Iron Deficiency Anemia Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Trending Reports by DelveInsight:

Adalimumab Biosimilar Market  | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Iron Deficiency Anemia Market Analysis 2034 | Iron Deficiency Anemia Therapies, Clinical trials, Iron Deficiency Anemia prevalence, Treatment Algorithms | Akebia Therapeutics, Shield Therapeutics

“Interstitial Cystitis market”

DelveInsight’s “Interstitial Cystitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Interstitial Cystitis, historical and forecasted epidemiology as well as the Interstitial Cystitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Interstitial Cystitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Interstitial Cystitis Market Forecast

Some of the key facts of the Interstitial Cystitis Market Report: 

• The Interstitial Cystitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032).

• According to DelveInsight’s analysis, the interstitial cystitis market size reached USD 1.8 billion in 2021 across the 7MM, and is expected to grow with a significant CAGR by 2032.

• DelveInsight’s analysis reveals that the overall diagnosed prevalent population of interstitial cystitis in the 7MM was reported as 2.5 million in 2021. Within this, the diagnosed prevalent population of interstitial cystitis patients in the United States specifically was identified to be 1.6 million in the same year.

• Key Interstitial Cystitis Companies: Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and others

• Key Interstitial Cystitis Therapies: Elmiron, RIMSO-50, KRP-116D, Certolizumab pegol (Cimzia), LP-08, GRT6010, ASP6294, SI-722, and others

• The total diagnosed prevalent population of Interstitial Cystitis in the 7 major markets was found to be 2,343,164 in 2018. In case of Interstitial Cystitis patients in the United States, the diagnosed prevalent cases were found to be 1,512,400 cases.

• The prevalent population of Interstitial Cystitis in the United States was found to be 5,894,905 in 2018.

• DelveInsight has analyzed severity-based data for Interstitial Cystitis. Interstitial Cystitis can be divided as three types based on this data, namely, mild, moderate and severe type. It was found that in the United States the number of cases of mild, moderate and severe were 544,500, 756,200 and 211,800 respectively.

• Expected Launch of potential therapies may increase the market size in the coming years, assisted by an increase in the diagnosed prevalent population of Interstitial Cystitis. Owing to the positive outcomes of the several products during the developmental stage by key players such as Kyorin Pharmaceutical, UCB Pharma, Lipella Pharmaceuticals, Grünenthal and Astellas Pharma, the market is expected to witness a significant positive shift in the Interstitial Cystitis Market Size.

• The Interstitial Cystitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Interstitial Cystitis pipeline products will significantly revolutionize the Interstitial Cystitis market dynamics.

• In Oct 2023, Glycologix, Inc. announced the treatment of the first patient in a pilot clinical study evaluating GLX-100 as a novel treatment for Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS). The multi-center pilot trial is designed to assess the safety, tolerability and effectiveness of GLX-100 in participants with IC/BPS and is expected to enroll up to 40 women with results anticipated in 2024.

• In June 2023, Hyloris Pharmaceuticals SA (Euronext Brussels: HYL), a specialty biopharma company committed to addressing unmet medical needs through reinventing existing medications, today announces that the first patient has been enrolled in a 4-arm Phase 2 trial2 of AlenuraTM, comparing the product candidate to both of its individual components (heparin and lidocaine)3 as well as placebo.

Interstitial Cystitis Overview

Interstitial Cystitis, also known as Painful Bladder Syndrome, is a persistent condition characterized by bladder pressure, bladder pain, and occasionally pelvic discomfort. The severity of pain can vary from mild to severe levels. The bladder, a hollow muscular organ responsible for storing urine, expands until it’s full, signaling the brain through pelvic nerves when it’s time to urinate, typically prompting the urge to urinate. However, with IC, these signals become confused, leading patients to feel the need to urinate more frequently and with smaller volumes of urine than usual. This condition predominantly affects women and can significantly impact their quality of life over the long term. While there’s no definitive cure, medications and various therapies may provide some relief.

There are two main types of IC: Non-Ulcerative, which accounts for approximately 90% of IC cases, is characterized by pinpoint hemorrhages known as glomerulations. The other type, Ulcerative, affects about 5-10% of patients and is primarily identified by Hunner’s ulcers, along with patches that bleed on the bladder walls. Hunner’s ulcers, also referred to as “Hunner’s lesions” or “Hunner’s patches,” are specific areas of inflammation on the bladder wall that define the “classic” form of IC. While Hunner’s ulcers are a key diagnostic feature for IC, this classic form only affects a small percentage of patients, typically presenting with more severe symptoms compared to those with non-ulcerative IC.

Get a Free sample for the Interstitial Cystitis Market Forecast, Size & Share Analysis Report: https://www.delveinsight.com/sample-request/interstitial-cystitis-market-forecast 

Interstitial Cystitis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Interstitial Cystitis Epidemiology Segmentation:

The Interstitial Cystitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Prevalence of Interstitial Cystitis

• Prevalent Cases of Interstitial Cystitis by severity

• Gender-specific Prevalence of Interstitial Cystitis

• Diagnosed Cases of Episodic and Chronic Interstitial Cystitis

Download the report to understand which factors are driving Interstitial Cystitis epidemiology trends @ Interstitial Cystitis Epidemiology Forecast

Interstitial Cystitis Therapies

• Elmiron

• RIMSO-50

• KRP-116D

• Certolizumab pegol (Cimzia)

• LP-08

• GRT6010

• ASP6294

• SI-722

Interstitial Cystitis Key Companies

• Merck & Co

• Teva Pharmaceutical Industries

• Integrative Therapeutics

• Lipella Pharmaceuticals

• Addex Therapeutics

• Seikagaku Corporation

• UCB

• Alivio Therapeutics

• Imbrium Therapeutics

• Ironwood Pharmaceuticals

Discover more about therapies set to grab major Interstitial Cystitis market share @ Interstitial Cystitis Treatment Landscape

Interstitial Cystitis Market Outlook

As per the Interstitial Cystitis Association (ICA), interstitial cystitis (IC) is a bladder disorder typically characterized by a variety of symptoms. Most individuals with IC experience recurring pelvic pain, pressure, or discomfort in the bladder and pelvic area, along with urinary frequency and urgency (a strong urge to urinate). IC is also known by various other names such as painful bladder syndrome (PBS), bladder pain syndrome (BPS), and chronic pelvic pain. It is estimated that approximately 3–8 million women in the United States, constituting about 3–6% of all women in the US, may suffer from IC. Additionally, 1–4 million men are affected by IC, although this number is likely underestimated because IC in men may often be misdiagnosed as another condition, such as chronic prostatitis/chronic pelvic pain syndrome.

Oral pentosan polysulfate sodium (PPS) and intravesical dimethyl sulfoxide (DMSO) are the only treatments approved by the US Food and Drug Administration (FDA) for alleviating IC symptoms. Fortunately, various other therapies are commonly utilized either individually or in combination for managing IC. Among orally administered therapies, only Elmiron (Pentosan polysulfate sodium; Janssen Pharmaceuticals) is FDA-approved for IC treatment, receiving approval in September 1996. Pentosan Polysulfate is a semi-synthetic heparin-like glycosaminoglycan. On the other hand, intravesical instillations involving anesthetic solutions are employed to alleviate bladder pain, along with heparin agents believed to repair damaged urothelium. The American Urological Association’s practice guideline for IC suggests bladder instillations as a second-line treatment option when dietary modifications, stress management, and over-the-counter products prove insufficient. Bladder instillations, also known as bladder cocktails, involve introducing mixtures of medications directly into the bladder.

Common types of instillations include Alkalinized Lidocaine and Heparin, DMSO, Sodium Hyaluronate, and BCG. Among these, Dimethyl sulfoxide (DMSO, marketed as RIMSO-50 by Mylan Pharmaceutical) was the first and remains the only FDA-approved bladder instillation specifically for Interstitial Cystitis (IC), receiving approval in 1978. Its precise mechanism of action is not fully understood, but it is believed to have several beneficial effects including anti-inflammatory, antispasmodic, pain-relieving properties, and increasing bladder capacity by breaking down scar tissue and preventing the formation of collagen, a protein involved in scar tissue formation.

Current IC treatment strategies involve the use of interventions either as single therapies (monotherapies) or in combination (combination therapies). Monotherapy options include oral medications, intravesical instillations, and other treatment modalities, while combination therapy entails using one or more of these therapies together.

Scope of the Interstitial Cystitis Market Report

• Study Period: 2019–2032

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Interstitial Cystitis Companies: Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics, Inc., Lipella Pharmaceuticals, Inc., Addex Therapeutics, Seikagaku Corporation, UCB, Alivio Therapeutics, Imbrium Therapeutics, Ironwood Pharmaceuticals, and others

• Key Interstitial Cystitis Therapies: Elmiron, RIMSO-50, KRP-116D, Certolizumab pegol (Cimzia), LP-08, GRT6010, ASP6294, SI-722, and others

• Interstitial Cystitis Therapeutic Assessment: Interstitial Cystitis current marketed and Interstitial Cystitis emerging therapies

• Interstitial Cystitis Market Dynamics: Interstitial Cystitis market drivers and Interstitial Cystitis market barriers 

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Interstitial Cystitis Unmet Needs, KOL’s views, Analyst’s views, Interstitial Cystitis Market Access and Reimbursement 

 Table of Contents 

1. Interstitial Cystitis Market Report Introduction

2. Executive Summary for Interstitial Cystitis

3. SWOT analysis of Interstitial Cystitis

4. Interstitial Cystitis Patient Share (%) Overview at a Glance

5. Interstitial Cystitis Market Overview at a Glance

6. Interstitial Cystitis Disease Background and Overview

7. Interstitial Cystitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Interstitial Cystitis 

9. Interstitial Cystitis Current Treatment and Medical Practices

10. Interstitial Cystitis Unmet Needs

11. Interstitial Cystitis Emerging Therapies

12. Interstitial Cystitis Market Outlook

13. Country-Wise Interstitial Cystitis Market Analysis (2019–2032)

14. Interstitial Cystitis Market Access and Reimbursement of Therapies

15. Interstitial Cystitis Market Drivers

16. Interstitial Cystitis Market Barriers

17.  Interstitial Cystitis Appendix

18. Interstitial Cystitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports: 

Interstitial Cystitis Pipeline  

“Interstitial Cystitis Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Interstitial Cystitis market. A detailed picture of the Interstitial Cystitis pipeline landscape is provided, which includes the disease overview and Interstitial Cystitis treatment guidelines. 

Interstitial Cystitis Epidemiology 

DelveInsight’s ‘Interstitial Cystitis Epidemiology Forecast to 2032’ report delivers an in-depth understanding of the disease, historical and forecasted Interstitial Cystitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Interstitial Cystitis Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest EMA, PDMA, FDA Approvals by DelveInsight | Merck & Co, Teva Pharmaceutical Industries, Integrative Therapeutics